Diaceutics is pleased to report another period of strong organic growth, platform adoption, and focused commercial execution. These results reflect the strength of our model and our commitment to delivering value for customers across the precision medicine landscape.
Read the full update here: https://lnkd.in/ebxKkbmt
Key Highlights:
• Revenue growth of 22% on a constant currency basis to £14.6 million in H1 2025 representing a 3-year CAGR of 25%
• Order book of £29.4 million, with £8.8 million already contracted for H2 2025 delivery
• Annual Recurring Revenue (ARR) up 16% to £16.4 million, now representing 70% of total H1 revenues
• 17% growth in number of customer therapeutic brands Diaceutics is working with
• New enterprise-wide agreement signed, bringing total to eight representing £10.1 million in ARR
• Diaceutics continues to demonstrate it’s ability to be the primary commercialization partner for pharma and biotech companies launching precision medicines
• Strong balance sheet, with no debt and £10.4 million in cash
Ryan Keeling, Diaceutics’ Chief Executive Officer, commented: Our continued growth demonstrates the significant value our customers place on our solutions, reflected by the increasing number of therapeutic brands we are working with. Our deepening engagement with enterprise clients, consistent growth in therapeutic brand count, and strong pipeline coverage into the historically stronger second half of the year, gives us confidence in delivering against both growth and profitability targets for the full year.”